IMMUNOLOGY2026™ Conference Recordings For Attendees-The role of the transcription factor Blimp-1 in T cells in anti-PD1 immunotherapy in non-small cell lung cancer

The role of the transcription factor Blimp-1 in T cells in anti-PD1 immunotherapy in non-small cell lung cancer

Video Transcription

Video Summary

The presentation showed that BLIMP1, a transcriptional repressor, is elevated in T cells within non-small cell lung cancer and may contribute to immune escape. In mouse models, deleting BLIMP1 in T cells reduced tumor burden, lowered Treg cells, increased TH1/TBET responses, and enhanced cytotoxic activity. Anti-PD-1 treatment further improved antitumor effects and reduced BLIMP1 while boosting T-cell function. Human patient samples showed similar BLIMP1/TBET shifts, especially in advanced disease and Tregs. Overall, the study suggests BLIMP1 is a promising target to strengthen anti-PD-1 immunotherapy in lung cancer.

Meta Tag

Date April 18, 2026 2:00 PM - 2:15 PM

Room 205

Session Molecular Mechanisms of Tumor Immunity

Speaker Susetta Finotto

Track Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

Year 2026

Keywords

BLIMP1

non-small cell lung cancer

T cells

anti-PD-1 immunotherapy

tumor immune escape

April 18, 2026 2:00 PM - 2:15 PM

205

Molecular Mechanisms of Tumor Immunity

Susetta Finotto

Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

2026